Post-earnings recap
Reported
Tue, Dec 12, 2017
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
25%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Arrowhead Pharmaceuticals reported a loss that was greater than expected, which typically raises concerns among investors. However, the stock still saw a slight increase of 1.14%, likely due to investors focusing on the company's long-term potential and ongoing development efforts. The lack of guidance may leave some uncertainty about future performance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.14 | N/A | -74.76% |
| Revenue | N/A | N/A | N/A |
Management expressed concern over current challenges but highlighted their commitment to product development. They did not offer any forward guidance.
Management acknowledged the challenges faced this quarter.
They emphasized ongoing efforts to improve product development.
No specific guidance was provided for future performance.